^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Chong Kun Dang, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    3d
    A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients with Polypoidal Choroidal Vasculopathy (PCV) (ChiCTR2500115109)
    P4, N=174, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    3d
    A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants with Neovascular Age-Related Macular Degeneration – The STELLAR Trial (ChiCTR2500115643)
    P3, N=332, Recruiting, Shanghai General Hospital; Shanghai Langsheng Biotechnology Co., Ltd
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    7d
    TELeMAC: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (clinicaltrials.gov)
    P3, N=16, Terminated, Centre Hospitalier Universitaire Dijon | N=46 --> 16 | Trial completion date: Dec 2027 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Mar 2025; very rare disease, many difficulties in recruiting patients, inclusion rate far too slow, making it impossible to meet the main objective within a reasonable timeframe. the sponsor therefore decided to stop the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    8d
    A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov)
    P4, N=174, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    28d
    Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) (clinicaltrials.gov)
    P3, N=332, Not yet recruiting, Innostellar Biotherapeutics Co.,Ltd
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    AcTED: Anti-VEGF Therapy for Acute Thyroid Eye Disease (clinicaltrials.gov)
    P2, N=11, Completed, Massachusetts Eye and Ear Infirmary | Recruiting --> Completed | N=24 --> 11
    Trial completion • Enrollment change
    |
    Eylea (aflibercept intravitreal)
    1m
    A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema (clinicaltrials.gov)
    P=N/A, N=3000, Active, not recruiting, Bayer | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    2ms
    Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=54, Recruiting, Saglik Bilimleri Universitesi | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    2ms
    The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=38, Completed, Asan Medical Center | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    2ms
    SAHLVE: The Sahlgrenska Anti-VEGF Study (clinicaltrials.gov)
    P2, N=402, Active, not recruiting, Vastra Gotaland Region | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> May 2027 | Trial primary completion date: Sep 2024 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Eylea (aflibercept intravitreal)
    3ms
    Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=54, Not yet recruiting, Saglik Bilimleri Universitesi
    New trial • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    3ms
    ARTEMIS: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=284, Recruiting, Adverum Biotechnologies, Inc. | Trial completion date: Mar 2030 --> Nov 2030 | Trial primary completion date: Apr 2027 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)